LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-027-999	10/735,408
APPLICANT	**CONFIRMATION NO.**
Storer, et al.	2099
FILING DATE	**ART UNIT**
December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A01	3,074,929	1/22/63	Hitchings, et al.	
	A02	3,116,282	12/31/63	Hunter	
	A03	3,891,623	6/24/75	Vorbruggen, et al.	
	A04	3,480,613	11/25/69	Walton	
	A05	4,209,613	6/24/80	Vorbruggen	
	A06	4,605,659	8/12/86	Verheyden, et al.	
	A07	4,689,404	8/25/87	Kawada, et al.	
	A08	4,754,026	6/28/88	Kawada, et al.	
	A09	4,814,477	3/21/89	Wijnberg, et al.	
	A10	4,880,784	11/14/89	Robins, et al.	
	A11	5,034,394	7/23/91	Daluge	
	A12	5,122,517	6/16/92	Vince, et al.	
	A13	5,156,797	10/26/93	Chou, et al.	
	A14	5,200,514	4/06/93	Chu	
	A15	5,371,210	12/06/94	Chou, et al.	
	A16	5,372,808	12/13/94	Blatt, et al.	
	A17	5,401,861	3/28/95	Chou, et al.	
	A18	5,539,116	7/23/96	Liotta, et al.	
	A19	5,565,438	10/15/96	Chu, et al.	
	A20	5,567,688	10/22/96	Chu, et al.	
	A21	5,587,362	12/24/96	Chu, et al.	
	A22	5,606,048	2/25/97	Chou, et al.	
	A23	5,676,942	10/14/97	Testa, et al.	
	A24	5,696,277	12/09/97	Hostetler, et al.	
	A25	5,738,845	4/14/98	Imakawa	
	A26	5,744,600	4/28/98	Mansuri, et al.	
	A27	5,750,676	5/12/98	Vorbruggen, et al.	
	A28	5,763,418	6/09/98	Matsuda, et al.	
	A29	5,780,617	7/14/98	Van den Bosch, et al.	
	A30	5,789,608	8/04/98	Glazier	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A31	5,821,357	10/13/98	Chou, et al.	
	A32	5,830,455	11/3/98	Valtuena, et al.	
	A33	5,849,696	12/15/98	Chretien, et al.	
	A34	5,908,621	6/1/99	Glue, et al.	
	A35	5,928,636	7/27/99	Alber, et al.	
	A36	5,942,223	8/24/99	Bazer, et al.	
	A37	5,977,061	11/2/99	Holy, et al.	
	A38	5,977,325	11/2/99	McCarthy, et al.	
	A39	5,980,884	11/9/99	Blatt, et al.	
	A40	6,002,029	12/14/99	Hostetler, et al.	
	A41	6,063,628	5/16/00	Loeb, et al.	
	A42	6,140,310	10/31/00	Glazier	
	A43	6,156,501	12/05/00	McGall, et al.	
	A44	6,172,046	1/09/01	Albrecht	
	A45	6,252,060	6/26/01	Hostetler	
	A46	6,277,830	8/21/01	Ganguly, et al.	
	A47	6,312,662	11/06/01	Erion, et al.	
	A48	6,340,690	1/22/02	Bachand, et al.	
	A49	6,348,587	2/19/02	Schinazi, et al.	
	A50	6,369,040	4/09/02	Acevedo, et al.	
	A51	6,395,716	5/28/02	Gosselin, et al.	
	A52	6,436,437	8/20/02	Yatvin, et al.	
	A53	6,444,652	9/3/02	Gosselin, et al.	
	A54	6,448,392	9/10/02	Hostetler, et al.	
	A55	6,455,508	9/24/02	Ramasamy, et al.	
	A56	6,458,772	10/01/02	Zhou, et al.	
	A57	6,458,773	10/01/02	Gosselin, et al.	
	A58	6,472,373	10/29/02	Albrecht	
	A59	6,495,677	12/17/02	Ramasamy et al.	
	A60	6,566,365	5/20/03	Storer	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A61	6,573,248	6/03/03	Ramasamy, et al.	
	A62	6,599,887	7/29/03	Hostetler, et al.	
	A63	6,605,614	8/12/03	Bachand, et al.	
	A64	6,660,721	12/9/03	Devos, et al.	
	A65	6,752,981	6/22/04	Erion, et al.	
	A66	6,777,395	8/17/04	Bhat, et al.	
	A67	6,784,161	8/31/04	Ismaili, et al.	
	A68	6,784,166	8/31/04	Devos, et al.	
	A69	6,787,526	9/7/04	Bryant, et al.	
	A70	6,812,219	11/2/04	LaColla, et al.	
	A71	6,815,542	11/9/04	Hong, et al.	
	A72	6,831,069	12/14/04	Tam, et al.	
	A73	6,846,810	1/25/05	Martin, et al.	
	A74	6,875,751	4/5/05	Imbach, et al.	
	A75	6,908,924	6/21/05	Watanabe, et al.	
	A76	6,911,424	6/28/05	Schinazi, et al.	
	A77	6,914,054	7/05/05	Sommadossi, et al.	
	A78	6,927,291	8/9/05	Jin, et al.	
	A79	6,946,450	9/20/05	Gosselin, et al.	
	A80	6,965,033	11/15/05	Jiang, et al.	
	A81	7,056,895	6/6/06	Ramasamy, et al.	
	A82	7,094,770	8/22/06	Watanabe, et al.	
	A83	7,101,861	9/05/06	Sommadossi, et al.	
	A84	7,105,493	9/12/06	Sommadossi, et al.	
	A85	7,105,499	9/12/06	Carroll, et al.	
	A86	7,125,855	10/24/06	Bhat, et al.	
	A87	7,148,206	12/12/06	Sommadossi, et al.	
	A88	7,157,441	1/02/07	Sommadossi, et al.	
	A89	7,163,929	1/16/07	Sommadossi, et al.	
	A90	7,169,766	1/30/07	Sommadossi, et al.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A91	7,202,224	4/10/07	Eldrup, et al.	
	A92	2002/0035085	3/21/02	Somadossi, et al.	
	A93	2002/0052345	5/2/02	Erion, et al.	
	A94	2002/0055473	5/9/02	Ganguly, et al.	
	A95	2002/0055483	5/9/02	Watanable, et al.	
	A96	2002/0099072	7/25/02	Bachand, et al.	
	A97	2002/0127203	9/12/02	Albrecht	
	A98	2002/0147160	10/10/02	Bhat, et al.	
	A99	2002/0173490	11/21/02	Jiang, et al.	
	A100	2002/0198171	12/26/02	Schinazi, et al.	
	A101	2003/0008841	1/9/03	Devos, et al.	
	A102	2003/0028013	2/6/03	Hong, et al.	
	A103	2003/0039630	2/27/03	Albrecht	
	A104	2003/0053986	3/20/03	Zahm	
	A105	2003/0055013	3/20/03	Brass	
	A106	2003/0083306	5/1/03	Imbach, et al.	
	A107	2003/0083307	5/1/03	Devos, et al.	
	A108	2003/0087873	5/8/03	Stuyver, et al.	
	A109	2003/0124512	7/3/03	Styuver	
	A110	2003/0225028	12/4/03	Gosselin, et al.	
	A111	2003/0225029	12/4/03	Stuyver	
	A112	2003/0225037	12/4/03	Storer, et al.	
	A113	2003/0236216	12/25/03	Devos, et al.	
	A114	2004/0002476	1/1/04	Stuyver et al.	
	A115	2004/0002596	1/1/04	Hong, et al.	
	A116	2004 0006002	1/08/04	Sommadossi, et al.	
	A117	2004/0023921	2/5/04	Hong, et al.	
	A118	2004/0059104	3/25/04	Cook, et al.	
	A119	2004/0063622	4/1/04	Sommadossi, et al.	
	A120	2004/0063658	4/1/04	Roberts et al.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-027-999	10/735,408
APPLICANT	**CONFIRMATION NO.**
Storer, et al.	2099
FILING DATE	**ART UNIT**
December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A121	2004/0067901	4/8/04	Bhat et al.	
	A122	2004/0072788	4/15/04	Bhat et al.	
	A123	2004/0077587	4/22/04	Sommadossi, et al.	
	A124	2004/0097461	5/20/04	Sommadossi, et al.	
	A125	2004/0097462	5/20/04	Sommadossi, et al.	
	A126	2004/0101535	5/27/04	Sommadossi, et al.	
	A127	2004/0102414	5/27/04	Sommadossi, et al.	
	A128	2004/0110717	6/10/04	Carroll, et al.	
	A129	2004/0110718	6/10/04	Devos, et al.	
	A130	2004/0121980	6/24/04	Martin, et al.	
	A131	2005/0124532	6/09/05	Sommadossi, et al.	
	A132	2004/0147464	7/29/04	Roberts, et al.	
	A133	2004/0229839	11/18/04	Babu, et al.	
	A134	2004/0248844	12/9/04	Ismaili, et al.	
	A135	2004/0259934	12/23/04	Olsen, et al.	
	A136	2004/0266722	12/30/04	Devos, et al.	
	A137	2004/0266723	12/30/04	Otto, et al.	
	A138	2004/0266996	12/30/04	Microbiologica Quimica E Farmaceutica Ltd., Brazil	
	A139	2005/0009737	1/13/05	Clark, et al.	
	A140	2005/0020825	1/27/05	Storer, et al.	
	A141	2005/0031588	2/10/05	Sommadossi, et al.	
	A142	2005/0038240	2/17/05	Connolly, et al.	
	A143	2005/0090463	4/28/05	Roberts, et al.	
	A144	2005/0101550	5/12/05	Roberts, et al.	
	A145	2005/0107312	5/19/05	Keicher, et al.	
	A146	2005/0113330	5/26/05	Imbach, et al.	
	A147	2005/0119200	6/2/05	Roberts, et al.	
	A148	2005/0137141	6/23/05	Hilfinger, et al.	
	A149	2005/0215511	9/29/05	Roberts, et al.	
	A150	2006/0040890	3/23/06	Martin; Joseph Armstrong, et al.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
	A151	2006/0111311	5/25/06	Keicher, et al.	
	A152	2006/0194835	8/31/06	Dugourd, et al.	
	A153	2006/0241064	10/26/06	Roberts, et al.	
	A154	2007/0015905	1/18/07	LaColla, et al.	
	A155	2007/0203334	8/30/07	Mayes, et al.	
	A156	10/845,976	5/14/04	Storer, et al.	
	A157	11/005,443	12/06/04	Gosselin, et al.	
	A158	11/516,928	9/06/06	Sommadossi, et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B01	CA 2252144	4/16/00	Miller, et al.		
	B02	DD 140254	2/20/80	Barwolff, et al.	English Abstract Provided	
	B03	DE 1 919 307	1/14/71	Niedballa, et al.	English Abstract Provided	
	B04	DE 2 122 991	11/16/72	Vorbruggen, et al.	English Abstract Provided	
	B05	DE 2 508 312	9/02/76	Vorbruggen, et al.	English Abstract Provided	
	B06	DE 4 224 737	2/03/94	Schott	English Abstract Provided	
	B07	DE 102005012681	09/21/06	Weber, Lutz	English Abstract Provided	
	B08	EP 0 288 847	4/16/88	Dobler, et al.		
	B09	EP 0 352 248	1/24/90	Medivir AB		
	B10	EP 0 494 119	1/03/92	Belleau, et al.		
	B11	EP 0 587 364	3/16/94	Britton, et al.		
	B12	EP 0 742 287	11/13/96	McGall, et al.		
	B13	EP 0 747 389	12/11/96	Taiho Pharmaceutical Co Ltd		
	B14	FR 1 521 076	4/12/68	Walton	English Abstract Provided	
	B15	FR 1 581 628	9/19/69	Merck & Co. Inc.	English Abstract Provided	
	B16	FR 2 662 165	11/22/91	Univ. Pier et Curie	English Abstract Provided	
	B17	GB 924246	4/24/63	Wellcome Foundation, Ltd.		
	B18	GB 984877	3/03/65	Zellstofffabrik Waldhof		

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B19	GB 1,163,103	9/4/69	Merck & Co. Inc.		
	B20	GB 1,187,824	5/02/66	Walton		
	B21	GB 1,209,654	10/21/70	Walton		
	B22	GB 1,542,442	3/21/79	Schering AG		
	B23	JP 48048495	9/21/71	Kojin Co., Ltd.	English Abstract Provided	
	B24	JP 71021872		Sankyo Co., Ltd.	English Abstract Provided	
	B25	JP 09059292	3/04/97	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B26	JP 2091022	3/30/90	Univ. of Minnesota	English Abstract Provided	
	B27	JP 06135988	5/17/94	Toagosei Chimical Ind., Ltd.	English Abstract Provided	
	B28	JP 06211890	8/02/94	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B29	JP 06228186	8/16/94	Yamasa Shoyu Co., Ltd.	English Abstract Provided	
	B30	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho	English Abstract Provided	
	B31	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.	English Abstract Provided	
	B32	JP 61263996	11/21/86	Hong	English Abstract Provided	
	B33	JP 63215694	9/8/88	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B34	WO 92/15308	9/17/92	Painter, et al.		
	B35	WO 92/18517	10/29/92	Cheng, et al.		
	B36	WO 94/001117	1/20/94	Koszalka, et al.		
	B37	WO 98/016184	4/23/98	ICN Pharmaceuticals		
	B38	WO 99/023104	5/14/99	Klecker, et al.		
	B39	WO 99/052514	10/21/99	Eli Lilly and Co.		
	B40	WO 00/009531	2/24/00	Novirio Pharmaceuticals, Ltd.		
	B41	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B42	WO 01/068663	9/20/01	Ribapharm Corp.		
	B43	WO 01/091737	12/06/01	Sommadossi, et al.		
	B44	WO 02/003997	1/17/02	Ribapharm, Inc.		
	B45	WO 02/070533	9/12/02	Pharmasset Ltd.		
	B46	WO 02/094289	11/28/02	F. Hoffmann-La Roche AG		
	B47	WO 02/100415	12/19/02	F. Hoffmann-La Roche AG		
	B48	WO 03/026589	4/3/03	Idenix Pharma.; CNRS; U. Montp.		

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B49	WO 03/026675	4/3/03	Idenix Pharma.; CNRS; U. Montp.		
	B50	WO 03/039523	5/15/03	Wengel		
	B51	WO 03/051899	6/26/03	Ribapharm Inc.		
	B52	WO 03/061385	7/31/03	Ribapharm Inc.		
	B53	WO 03/061576	7/31/03	Ribapharm Inc.		
	B54	WO 03/062255	7/31/03	Ribapharm Inc.		
	B55	WO 03/062256	7/31/03	Ribapharm Inc.		
	B56	WO 03/062257	7/31/03	Ribapharm Inc.		
	B57	WO 03/063771	8/7/03	Pharmasset Inc.		
	B58	WO 03/068162	8/21/03	Pharmasset Inc.		
	B59	WO 03/068164	8/21/03	Pharmasset Inc.		
	B60	WO 03/068244	8/21/03	Merck & Co.; Isis Pharmaceuticals Inc.		
	B61	WO 03/072757	9/04/03	Biota Inc.		
	B62	WO 03/093290	11/13/03	Genelabs Technologies Inc.		
	B63	WO 03/099840	12/04/03	Eldrup, et al.		
	B64	WO 03/100017	12/04/03	Eldrup, et al.		
	B65	WO 03/105770	12/24/03	Eldrup		
	B66	WO 04/000858	12/31/03	Merck & Co. Isis Pharmaceuticals		
	B67	WO 04/002422	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B68	WO 04/002999	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B69	WO 04/003000	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B70	WO 04/007512	1/22/04	Merck & Co. Isis Pharmaceuticals		
	B71	WO 04/028481	4/08/04	Genelabs Technologies, Inc.		
	B72	WO 04/041203	5/21/04	Xenoport, Inc., USA		
	B73	WO 04/043977	5/27/04	Prakush, et al.		
	B74	WO 04/043978	5/27/04	Baker, et al.		
	B75	WO 04/044132	5/27/04	Baker, et al.		
	B76	WO 04/046159	6/03/04	F. Hoffmann-La Roche AG		
	B77	WO 04/046331	6/03/04	Idenix Cayman Limited		
	B78	WO 04/052899	6/24/04	Idenix Cayman Limited		

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
	B79	WO 04/058792	7/15/04	Idenix Cayman Limited		
	B80	WO 04/065398	8/5/04	Ribapharm, Inc.		
	B81	WO 04/072090	8/26/04	Merck & Co., Inc.		
	B82	WO 04/080466	9/23/04	Ribapharm, Inc.		
	B83	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B84	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B85	WO 04/106356	12/9/04	Syddansk Universitet		
	B86	WO 05/003147	1/13/05	Pharmasset, Ltd.		
	B87	WO 05/012327	2/10/05	University College Cardiff Consultants Limted		
	B88	WO 05/020884	3/10/05	CENT NAT RECH SCI.		
	B89	WO 05/020885	3/10/05	Isis Pharmaceuticals, Inc., USA		
	B90	WO 05/021568	3/10/05	Biota, Inc.		
	B91	WO 05/030258	4/07/05	Dihedron Corp.		
	B92	WO 05/042556	5/12/05	Genelabs Technologies, Inc., USA		
	B93	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B94	WO 06/002231	1/05/06	Biocryst Pharmaceuticals, Inc.		
	B95	WO 06/012078	2/02/06	Merck & Co., Inc.		
	B96	WO 06/012440	2/02/06	Wang, et al.		
	B97	WO 06/016930	2/16/06	Intermune, Inc.		
	B98	WO 06/037028	4/06/06	CENT NAT RECH SCI		
	B99	WO 06/037227	4/13/06	Migenix Inc., Can.		
	B100	WO 06/063717	6/22/06	Universitaet Karlsruhe		
	B101	WO 06/065335	6/22/06	Merck & Co. Inc., USA		
	B102	WO 06/097323	9/21/06	Weber, Lutz		
	B103	WO 06/100087	9/28/06	Novartis A.G.		
	B104	WO 06/121820	11/16/06	Valeant Research & Development		
	B105	WO 06/130532	12/07/06	Novartis AG, Switz.		
	B106	WO 07/011777	1/25/07	Novartis A.-G., Switz.		
	B107	WO 07/025304	1/03/07	University of Oxford; Idenix Phamaceuticals; et al.		

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	Alt, et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Ptent and Specific Inhibitors of Hepatitis C Viral Translation." Arch. Virol. (1997) 142: 589-599.	
	C02	Alt, et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," Hepatology, 22:707-717 (1995).	
	C03	Altmann, et al., "The Synthesis of l'-Methyl Carbocyclic Thymidine and Its Effect on Nucleic Acid Duplex Stability," Synlett, Thieme Verlag. Stuttgart, De, 10:853-855 (1994).	
	C04	Awano, et al., "Nucleosides and Nucleotides, Part 144 Synthesis and Antiviral Activity of 5-Substituted (2's)-2'-Deoxy-2' –C-Methylycytidines and –Urdines," Archiv Der Pharmazie, VCH Verlagsgesellschaft Mbh, Weinheim, DE, vol. 329, February 1, 1996, (1996-02-01), pp. 66-72.	
	C05	Beigelman, et al., "A general method for synthesis of 3' –alkylnucleosides," Nucleic Acids Symp. Ser., vol. 9, 1981, pp. 115-118.	
	C06	Beigelman, et al., *Carbohydrate Res.*, 1987, 166: 219-232.	
	C07	Beigelman, et al., "Epimerization During the Acetolysis of 3-O-Acetyl-5-O-Benzoyl-1,2-o-Isopropylidene-3-C-Methyl-a, D-Ribofuranose. Synthesis of 3'-C-Methylnucleosides with the B-D-ribo-and a-D-arabino Configurations," Carbohydrate Research, 181:77-88 (1988).	
	C08	Berenguer, M., et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," Proccedings of the Association of American Physicians, 110(2), 98-112 (1998).	
	C09	Bhopale, Girish Mahadeorao, et al., "Emerging drugs for chronic hepatitis C," Hepatology Research (2005), 32(3), 146-153.	
	C10	Bianco, et al., "Sythesis of a New Carbocyclic Nucleoside Analog." *Tetrahedron Letters*, 38(36): 6433-6436.	
	C11	Billich, et al., "Nucleoside Phosphotransferase from Malt Sprouts." Biol. Chem. Hoppe-Seyler, Vol. 367, pp. 267-278, April 1986.	
	C12	Bio, et al., "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor." Journal of Organic Chemistry (2004), 69(19), 6257-6266.	
	C13	Bloch, A., et al., "The Role of the 5'-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," J. Med. Chem., 10(5):908-12 (September 1967).	
	C14	Boryski, et al., "Synthesis and Antiviral Activity of 3-Substituted Derivatives of 3,9-Dihydro-9-Oxo-5H-Imidazo[1,2-a]Purines, Tricyclic Analogues of Acyclovir and Ganciclovir." *J. Med. Chem.*, 34, 2380-2383.	
	C15	Brown & McFarlin, et al., J. Am. Chem. Soc. 1958, 80, 5372-76.	
	C16	Cappellacci, et al. "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1' –C-methyl denosine analogues," J. Med. Chem., vol. 45, 2002, pp. 1196-1202.	
	C17	Cappellacci, et al. "Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." Journal of Medicinal Chemistry (2005), 48(5), 1550-1562.	
	C18	Carroll, S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," *J. Biol. Chem.*, 278(14): 11979-11984 (2003).	
	C19	Carroll, S.S., "Nucleoside analog inhibitors of hepatitis C virus replication," Infectious Disorders: Drug Targets (2006), 6(1), 17-29.	
	C20	Chand, Pooran; et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." Collection Symposium Series (2005), 7(Chemistry of Nucleic Acid Components), 329-332.	
	C21	Chang, et al., *J. Biol. Chem.*, 1992, 267(20): 13938-42.	
	C22	Chiacchio, et al., "Stereoselective synthesis of 2'-amino-2',3'dideoxynucleosides by nitrone 1,3-dipolar cycloaddition: A new efficient entry toward d4T and its 2-methyl analougue," J. Org. Chem., vol. 64, 1999, pp.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		28-36.	
	C23	Chiaramonte, et al., "Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophates." Biochemistry 2001, 40, 14260-14267.	
	C24	Clark, et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." Journal of Medicinal Chemistry (2005), 48(17), 5504-5508.	
	C25	Coelmont, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methycytidine, the active component of valopicitabine," Antimicrobial Agents and Chemotherapy (2006), 50(10), 3444-3446.	
	C26	Cook, G.S., "Improving the treatment of hepatitis C infection in the UK," Expert Opinion on Pharmacotherapy, (2007) Vol. 8, No. 2, pp. 183-191.	
	C27	Cornberg, M., et al., "Present and future therapy for hepatitis C virus," Expert review of Anti-Infective Therapy, (2006) Vol. 4, No. 5, pp. 781-793.	
	C28	Czernecki, S., et al., "Synthesis of 2'-deoxy-2'-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase," Can. J. Chem., vol. 71, 1993, pp. 413-416.	
	C29	Czernecki, S., et al., "Synthesis of various 3'-branched 2', 3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," J. Org. Chem., 57: 7325-7328 (1992).	
	C30	Dalpiaz, et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." European Journal of Pharmacology (2002), 448(2-3), 123-131	
	C31	Davis, G.L., "New Therapies: Oral Inhibitors and Immune Modulators," Clinics in Liver Disease, (2006) Vol. 10, No. 4, pp. 867-880.	
	C32	Davisson, V.J., et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," J. Org. Chem., 52(9):1794-1801 (1987).	
	C33	Ding, et al., "Synthesis of 2'-β-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727.	
	C34	Ding, et al., "Synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 709-713	
	C35	Dutartre, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," Antimicrobial Agents and Chemotherapy, (2006) Vol. 50, No. 12, pp. 4161-4169.	
	C36	Eldrup, et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(21), 5284-5297.	
	C37	Eldrup, et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase.", Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(9), 2283-2295.	
	C38	Fahrquhar, et al., *J. Pharm. Sci.*, 1983, 72(3): 324.	
	C39	Faivre-Buet, et al., "Synthesis of 1'-Deoxypsicofuanosyl-Dexoynucleosides as Potential Anti-HIV Agents." Nucleosides & Nucleotides, vol. 11, no. 7, 1992, pages 1411-1424.	
	C40	Fedorov, et al., "3' –C-Branched 2' –deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties," J. Med. Chem., vol. 35, 1992, pp. 4567-4575.	
	C41	Fox, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," J. Am. Chem. Soc., 81: 178-187 (January 5, 1959).	
	C42	Franchetti, et al., "2' –C-Methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies," J. Med. Chem., vol. 41, 1998, pp. 1708-1715.	
	C43	Franchetti, et al., "Antitumor Activity of C-Methyl-β-D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors." Journal of Medicinal Chemistry (2005), 48(15), 4983-4989.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C44	Fujimori, et al., "A Convenient and Stereoselective Synthesis of 2'-Deoxy-[beta]-L-nucleosides," Nucleosides & Nucleotides, 11(2-4), 341-349 (1992); only CAPLUS abstract supplied.	
	C45	Furukawa, Y., et al. "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," Chem. Pharm. Bull., 16(6):1076-1080 (June 1968).	
	C46	Galderisi, U., et al., "Antisense oligonucleoties as therapeutic agents," Journal of Cellular Physiology, 181(2):251-257 (November 1999).	
	C47	Gallo, et al., "2'-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2'-hydroxyl Group." Tetrahedron, 57 (2001), 5707-5713.	
	C48	Girardet, et al., "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." Journal of Medicinal Chemistry (2000), 43(20), 3704-3713.	
	C49	Gretch, D.R., "Use and interpretation of HCV diagonostic tests in the clinical setting." Clinics in Live Disease, November 1997, Vol. 1, No. 3, pp. 547-557.	
	C50	Grouiller, *et al.*, "Novel-p-toluensesulfaonylation and Thionocarbonylation of Unprotected Thymine Nucleosides," *Synlett, 1993: 221-222 (1993).*	
	C51	Grouiller, et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." J. Pharm. Belg., 47(4), 381-3 (1992).	
	C52	Grunnagel, et al., "Preparation of D-Tagatose." Justus Liebigs Annalen der Chemie (1969), 721: 234-5.	
	C53	Haraguchi, *et al.*, "Preparation and Reactions of 2'-and 3'- Vinyl Bromides of Uracil Nucleosides: Versatile Synthons for Anti-HIV Agents," *Tetrahedron Letters, 32(28): 3391-94 (1991).*	
	C54	Haraguchi, *et al.*, "Stereoselective Synthesis of 1'-C-Branched Uracil Nucleosides from Uridine," *Nucleotides & Nucleosides, 14(3-5): 417-420 (1995).*	
	C55	Harry-O'Kuru, et al., "2'-C-alkylribonucleosides: Design, Synthesis and Conformation," *Nucleosides & Nucleotides,* vol. 16: 1457-60 (1997).	
	C56	Hassan, et al., "Nucleosides and Nucleotides 151: Conversion of (Z)-2'-(Cyanomethylene)-2'-Deoxyuridines into their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions." J. Org. Chem., vol. 61, 1996, pp. 6261-6267.	
	C57	Hassan, et al., "Nucleosides and Nucleotides 156: Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophernol Addition Reactions at the 2'-Position of 2'-[(Alkoxycarbonyl)methaylene]-2'-deoxyuridines: Conversion of (Z0-2'[(Alkoxycarbonyl)methylene]-2'-Deoxyuridines into their (E)-Isomers" J. Org. Chem., vol. 62, 1997, pp. 11-17.	
	C58	Hattori, H., et al., "Nucleosides and Nucleotides 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine and –uracil," *J. Med. Chem.*, 41: 2892-2902 (1998).	
	C59	Hayakawa, et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2'- and 3'-positions." Chemical & Pharmaceutical Bulletin (1987), 35(6), 2605-8.	
	C60	Hoard, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," J. Am Chem. Soc., 87(8):1785-1788 (April 20, 1965).	
	C61	Hodge, et al., "Amadori Rearrangement Products." Methods in Carbohydrate Chemistry (1963), 2: 99-107.	
	C62	Holy, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides fo the Pyrimidine Series," Collect. Czech. Chem. Commun., 37(12): 4072-4087 (1972).	
	C63	Hossain, et al., "Synthesis of 2'- and 3'-Spiro-isoxazolidine Derivatives of Thymidine & Their Conversions to 2',3'-dideoxy-2', 3'-didehydro-3'-C-substituted nucleosides by Radical Promoted Fragmentation," Tetrahedron Vol. 49, No. 44, pp. 10133-10156, (1993).	
	C64	Hrebabecky, et al., "Nucleic Acid Components and their Analogs: CXLIX: Synthesis of Pyrimidine Nucleosides Derived from 1-Deoxy-D-Psicose," *Coll Czech Chem Com.* 37: 2059-2064 (1974).	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C65	Hrebecky, et al., "Synthesis of 7- and 9b-D-Psicofuranosylguanine and Their 1'-Deoxy Derivatives." Collection Czechoslov. Chem. Commun., Vol. 39, 1974, pp. 2115-2123.	
	C66	Iglesias, et al., "Complete and Regioselective Deacetylation of Peracetylated Uridines Using a Lipase." Biotechnology Letters 22: 361-365, 2000.	
	C67	Iimori, et al., "2'-C-, 3'-C-, and 5'-C-Methylsangivamycins: conformational lock with the methyl group." Tetrahedron Letters (1991), 32(49), 7273-6.	
	C68	Iimori, et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." Nucleic Acids Symposium Series (1992), 27(Nineteenth Symposium on Nucleic Acids Chemistry, 1992), 169-70.	
	C69	Iino, T., et al., "Nucleosides and nucleotides 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'-deoxyuridines," Nucleosides & Nucleotides, 15(1-3): 169-181 (1996).	
	C70	Ikegashira, K., et al., "Discovery of conformationally constrained tetracylic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," Journal of Medicinal Chemistry, (30 Nov 2006) Vol. 449, No. 24, pp. 6950-6953.	
	C71	Imai, K., et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." J. Org. Chem., 34(6): 1547-1550 (June 1969).	
	C72	Itoh, et al., "Divergent and Sterocontrolled Approach to the Synthesis of Uracil Nucleosides Branched at the Anomeric Position," J Org Chem, 60(3): 656-662 (1995).	
	C73	Johnson, C.R., et al., "3' –C-Trifluoromethyl ribonucleosides," Nucleosides & Nucleosides, vol. 14, 1995, pp. 185-194.	
	C74	Kakefuda, et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-β-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." Tetrahedron (1993), 49(38), 8513-28	
	C75	Kamaike, K., et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine,]6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nuclesodies and Nucleotides, 15(1-3_: 749-769 (1996).	
	C76	Kaneko, M., et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20:1050-1053 (1972).	
	C77	Kawana, et al, "The Deoxygenatio of Tosylated Adenosine Derivatives with Grignard Reagents," Nucleic Acids Symp Ser, 17:37-40 (1986).	
	C78	Kim, et al., "A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein," Molecular Pharmaceutics (2004), 1(2), 117-127.	
	C79	Klumpp, et al., "The Novel Nucleoside Analog R1479 (4'-Azidocytidine) is a Potent Inhibitor of NS5B-dpendent RNA Synthesis and Hepatits C Virus Replication in Cell Culture." The Journal of Biological Chemistry, Vol. 281, No. 7, pp. 3793-3799, February 17, 2006.	
	C80	Kohn, et al., *J. Am. Chem. Soc.*, 1965, 87(23): 5475-80.	
	C81	Kotra, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosdes." J. Med. Chem. 1997, 40, 3635-3644.	
	C82	Kuhn, R., et al., "Uber eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
	C83	Lai, V.C.H., et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependant RNA polymerase," J. Virol., 73(12):10129-101136 (December 1999).	
	C84	Landowski, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics (2006), 316(2), 572-580.	
	C85	Lavaire, S., et al., "3'-deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," *Nucleosides & Nucleotides*, 17(12): 2267-2280 (1998).	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C86	Le Pogam, et al., "In Vitro Selected Con1 Subgenomic Replicons Resistant to 2'-C-Methyl-Cytidine or to R1479 Show Lack of Cross Resistance." Virology 351 (2006), 349-359.	
	C87	Le Pogam, et al., "Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymeras Inhibitors of the Hepatitis C Virus." Journal of Virology, Vol. 80, No. 12, June 2006, p. 6146-6154.	
	C88	Leyssen, P., et al., "Perspectives for the treatment of infections with Flaviviridae," *Clinical Microbiology Reviews* (Washington D.C.) 13(1): 67-82 (January 2000).	
	C89	Lin, T.S., et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," Tethrahedron Letters, 51(4): 1055-1068 (1995).	
	C90	Luh, et al. *Synthetic Communications*, 1978, 8(5): 327-33.	
	C91	Maga, Giovanni, et al., Lack of stereospecificity of suid pseudorabies virus thymidine kinase," Biochem. J., 294(2): 381-385 (1993).	
	C92	Mahmoudian, M., et al., "A Versatile Procedure for the Generation of Nucleoside 5'-Carboxylic Acids Using Nucleoside Oxidase," Tetrahedron, Elsevier Science Publishers Amsterday, NL, vol. 54, no. 28, July 9, 1998.	
	C93	Mansour, T.S., et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) Vol. 6, No. 1, pp. 1.	
	C94	Markland W., et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy, April 2000, Vol. 44, No. 4, pp. 859-866.	
	C95	Martin, J., et al., "Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides Against Human Immnodeficiency Virus (HIV-1). J. Med. Chem. 1990, 33, 2137-2145.	
	C96	Martin, X., et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy-β-D-piscofuranosyl)nucleoside," *Tetrahedron*, 50(22): 6689-6694 (1994).	
	C97	Matsuda, et al., "Alkyl Addition Reaction of Pyrimidine 2'-Ketaonucleosides: Synthesis of 2'-Branched-Chain Sugar Pyrimidne Nucleosides (Nucleosides and Nucleotides. LXXXI)" Chem Pharm Bull, Vol. 36(3):945-53 (1988).	
	C98	Matsuda, et al., "Nucleosides and Nucleotides 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentafuranosyl) pyrimidines: Synthesis of (2'S)-2-deoxy-2'-C-methylcytidine, and antileukemic nucleoside," Journal of Medicinal Chemistry, American Chemical Society Washington, US, vol. 34, 1991, pp. 234-239.	
	C99	Matsuda, et al., "Nucleosides and Nucleotides 104. Radical and Palladium-Catalyzed Deoxygenation of the Allylic Alcohol Systems in the Sugar Moiety of Pyrimidine Nucleosides." *Nucleosides & Nucleotides*, Dekker, New York, NY, U.S., vol. 11, no. 2/4, 1992, pages 197-226.	
	C100	Matsuda, et al., "Radical deoxygenation of tert-alcohols in 2' –branched-chain sugar pyrimidine nucleosides: synthesis and antileukemic activity of 2' –deoxy-2' (S)-methylcytidine," Chem. Pharm. Bull., vol. 35, 1987, pp. 3967-3970.	
	C101	Mikhailov, S.N., et al., "Hydrolysis of 2'- and 3'-C-methyluridine 2'-, 3'-monophosphates and Interconversion and dephosphorylation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of Uridine monophosphates," *J. Org. Chem.*, Vol. 57: 4122-26 (1992).	
	C102	Mikhailov, S.N., et al., "Substrate properties of C'-methylnucleoside and C'-methyl-2'-deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," *Nucleosides & Nucleotides*, 10(1-3): 339-343 (1991).	
	C103	Mikhailov, S.N., et al., "Synthesis and properties of 3' –C-methylnucleosides and their phosphoric esters," Carbohydrate Research, vol. 124, 1983, pp. 75-96.	
	C104	Miles, et al., "Circular Dichroism of Nucleoside Derivatives. IX. Vicinal Effects on the Circular Dichrosim of Pyrimidine Nucleosides." J. Am. Chem. Soc. 92(13): 3872-3881 (1970).	
	C105	Moore, et al., "Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase."	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Biochemistry (2002), 41(47), 14066-14075.	
	C106	Moiseyev, et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." FEBS Letters (1997), 404(2,3), 169-172	
	C107	Murai, et al., "A synthesis and an x-ray analysis of 2'-C-,3'-C- and 5'-C-methylsangivamycins," Heterocycles (1992), 33(1), 391-404.	
	C108	Nishiguchi, S., et al., "Methods to Detect Substitutions in the Interferon-Sensitivity-Determining Region of Hepatitis C virus 1b for Prediction of Response to Interferon Therapy," Hepatology. January 2001, Vol. 33, No. 1, pp. 241-247.	
	C109	Nishimura, T. et al. "Studies on Sythetic Nuclesides. Trimethylsilyl Derivatives of Pyrmidine and Purines," Chemical & Pharmaceutical Bulletin (1964), vol. 12, pp. 352-356.	
	C110	Oivanen, M., et al., "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3', 5'-cyclic monophosphates," *J. Chem. Soc. Perkin Trans. 2*, 1994: 309-314 (1994).	
	C111	Ong, S.P., et al., "Synthesis of 3' –C-methyladenosine and 3' –C-methyluridine diphosphates and their interaction with the ribonucleoside diphosphate reductase from Corynebacterium nephridii," Biochemistry, vol. 31, 1992, pp. 11210-11215.	
	C112	Pagliaro, L., et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI," Recenti Progressi in Medicina, (2006) Vol. 97, No. 12, pp. 741-750.	
	C113	Pierra, C., et al., "NM 283, and efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," Nucleosides, Nucleotides and Nucleic Acids (2005), 24(5-7), 767-770.	
	C114	Pierra, C., et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," Journal of Medicinal Chemistry (2006), 49(22), 6614-6620.	
	C115	Reist, et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." Journal of Organic Chemistry (1962), 27 3279-83.	
	C116	Robins, et al., "Purine Nucleosides. XXIX. The Synthesis of 2'-Deoxy-L-adenosine and 2'-Deoxy-L-guanosine and Their [alpha] Anomers," Journal of Organic Chemistry, 35(3), 636-639 (March 1970).	
	C117	Rong, et al., "The Synthesis and Conformation of 2'-and 3'-Hypermodified Tricyclic Nucleosides and Their Use in the Synthesis of Novel 2'- or 3'-Isomeric 4(7)-Substituted Isoxazolidine-nucleosides," Tetrahedron Vol. 50, No. 16, pp. 4921-4936. (1994).	
	C118	Roque-Afonso, AM, et al., "Performance of TRUGENE hepatitis C virus5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," Journal of Viral Hepatitis. September 2002, Vol. 9, Issue 5, pp. 385-389.	
	C119	Rosenthal, et al., "Branched-chain sugar nucleosides. Synthesis of 3' –C-ethyl (and 3' –C-butyl) uridine," Carbohydrate Research, vol. 79, 1980, pp. 235-242.	
	C120	Sakthivel, et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3deazaadenosine analogs." Tetrahedron Letters (2005), 46(22), 3883-3887.	
	C121	Sakthivel, et al. "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." Synlett (2005), (10), 1586-1590.	
	C122	Saladino, R., et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," J. chem. Soc., Perkin Trans. 1., 21: 3053-3054 (1994).	
	C123	Samano, et al., "Nucleic Acid Related Compounds. 77. 2',3'-Didehydro-2', 3'-Dideoxy-2' (and 3')-Methylnucleosides Via [3,3]-Sigmatropic Rearrangements of 2'(and 3')-Methylene-3'(and 2')-O-Thiocarbonyl Derivatives and Radical Reuction of a 2'-Chloro-3'Methylene Analogue," Can. J. Chem., 71: 186-191 (1993)	
	C124	Samano, et al., "Synthesis and Radical-Induced Ring-Opening Reactions of 2'-Deoxyadenosine-2'-Spirocyclopropane and its Uridine analogue. Mechanistic Probe for Ribonucleotide Reductases," J Am Chem Soc, 114: 4007-08 (1992)	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C125	Sandhu, et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." Drug Metabolism and Disposition (2004), 32(11), 1254-1259	
	C126	Sato, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." Tetrahedron Letters (1980), 21(20), 1971-4.	
	C127	Sato, et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." Bulletin of the Chemical Society of Japan (1983), 56(9), 2680-99.	
	C128	Savochkina, et al., "Substrate properties of c – methylnucleoside triphosphates in RNA syntheses catalyzed by e. coli RNA – polymeruse" Molecular Biology, 1989, v. 23, no. 6.	
	C129	Schiff, E.R., "Emerging strategies for pegylated interferon combination therapy," Nature Clinical Practice Gastoenterology and Hepatology, (2007) Vol. 4, No. SUPPL. 1, pp. S17-S21.	
	C130	Schmit, C., et al., "Synthesis of 2'-Deoxy-2' –Alpha-Monofluoromethyl and Trifluoromethylnucleosides," Synlett, Thieme Verlag, Stuttgart, DE, no. 4, 1994, pp. 241-242.	
	C131	Schmit, C., et al., "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," *Bioorg. & Med. Chem. Lett.*, 4(16): 1969-1974 (1994).	
	C132	Serafinowski, P.J., et al., "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," *Tetrahedron*, 56(2):333-339 (1999).	
	C133	Shalaby, et al., "Conformations and Structure Studies of Sugar Lactones in the Solid State. Part 11. The Molecular Structure of a-D-Glucosaccharino-Y-Lactone: 2-C-Mehtyl-D-Ribo-Pentono-1,4-lactone." Carbohydrate Research (1994), 264(2), 191-8.	
	C134	Sharma, et al., "Synthesis of 3' –Trifluoromethyl Nucleosides as Potential Antiviral Agents," Nucleosides, Nucleotides and Nucleic Acids, Marcel Dekker, Ann Harbor, MI, US, vol. 19, no. 4, 2000, pp. 757-774.	
	C135	Shim, Jae H., "Recent patents on nucleoside and nucleotide inhibitors for HCV," Recetn Patents on Anti-Infective Drug Discovery (2006), 1(3), 323-331.	
	C136	Sinkula, et al., *J. Pharm. Sci.*, 1975, 64: 181-210.	
	C137	Smith, et al., "Synthesis of new 2'-β-C-methyl related triciribine analogues as anti-HCV agents." Valeant Pharmaceuticals International, Costa Mesa, CA, USA. Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3517-3520.	
	C138	Song, et al., Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Medicated Transport," Moleculare Pharmaceutics (2005), 2(2), 157-167.	
	C139	Sorbera, L.A., et al., "Valopicitabine: anti-hepatitis C virus drug RNA –directed RNA polymerase (NS5B) inhibitor," Drugs of the Future (2006), 31 (4), 320-324.	
	C140	Spardari, et al., "L-Thmidine is Phosphorylated by Herpes Simplex Virus Type 1 Thymidine Kinase and Inhibits Viral Growth," Journal of Medicinal Chemistry, 35(22), 4214-4220 (1992).	
	C141	Stuyver, et al., "Ribonucleoside Analogue That Block Replication of Bovine Viral Diarrhea and Hepatits C Viruses in Culture." Antimicrobial Agents and Chemotherapy, Vol 47, No. 1, Jan. 2003, p. 244-254.	
	C142	Takenuki, et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." Chemical & Pharmaceutical Bulletin (1990), 38(11), 2947-52.	
	C143	Tritsch, D., et al., "3'-β-ethynyl and 2'-deoxy-3'-β-ethynyl adenosines: First 3'-β-branched adenosine substrates of adenosine deaminase," *Bioorg. & Med. Chem. Lett.*, 10: 139-141 (2000).	
	C144	Tronchet, et al. "72. Synthese et desamination enzymatique des C-hydroxymethyl-3'-et C-methyl-3' –beta-D-xylofurannosyl-9-adenin es," Helv. Chim. Acta, vol. 62, 1979, pp. 689-695.	
	C145	Tunitskaya, V.L., et al., "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," *FEBS Letters*, 400: 263-266 (1997).	
	C146	Tyrsted, G., et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," Biochem. Biophys. Acta., 155(2): 619-622 (February 26, 1968).	

LAI-2912074v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C147	Usui, H., et al., "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleotides & Nucleosides. LXIV)," Chem. Pharm. Bull., 34(1):15-23 (1986).	
	C148	Vassilev, V., et al., "Bovine Viral Diarrhea Virus Induced Apoptosis Correlates with Increased Intracellular Viral RNA Accumulation." *Virus Research*, 69: 95-107 (2000).	
	C149	Velazquez, et al., "Synthesis of '1-'3',5'-bis-0-(tert-butyldimethylsily)-beta-D-arabino-and beta-D-ribofuransoyl !cytosine!-2' –spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T," Tetrahedron, vol. 50, 1994, pp. 11013-11022.	
	C150	Verri, A., et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activetion of B-L-deoxyctidine analogs as antineolastic and antiviral agents," Molecular Pharmacology, 51(1): 132-138 (January 1997).	
	C151	Verri, a., et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Knase and Chemotherapeutic Uses of L-Nucleoside Analogues," Biochem. J., 328(1): 317-320 (November 15, 1997).	
	C152	Von Buren, et al., "Branched oligodeoxynucleotides: automated synthesis and triple helical hybridization studies." Tetrahedron (1995), 51(31), 8491-506.	
	C153	Von Janta-Lipiniski, M., et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified B-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular SNA Polymerases a, B, y, d and E Nor HIV-1 Reverse Transciptase," J. Medicinal Chemistry, 41(12): 2040-2046 (May 21, 1998).	
	C154	Wagner, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides," J. Org. Chem., 39(1):24-30 (1974).	
	C155	Walczak, K., et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," *Acta Chemica Scand.*, 45: 930-934 (1991).	
	C156	Walton, et al., "Branched-Chain Sugar Nucleosides: V. Synthesis and Antiviral Properties of Several Branched-Chain Sugar Nucleosides," *Antiviral Nucleosides,* Vol. 12: 306-309 (1969).	
	C157	Wohnsland, A., et al., "Viral determinants of resistance to treatment in patients with hepatitis C," Clinical Microbiology reviews, (2007) Vol. 20, No. 1, pp. 23-38.	
	C158	Wolf, et al., "New 2' –C-Branched-Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity," Synthesis, Georg Thieme Verlag. Stuttgart, DE, no. 8, August 1992 (1992-08), pp. 773-778.	
	C159	Wolfe, et al., Tetrahedron Letters, Vol. 36(42): 7611-14 (1995).	
	C160	Wu, et al., "A New Stereospecific Synthesis of [3.1.0] Cicyclic Cyclopropano Analog of 2',3'-Dideoxyuridine." *Tetrahedron*, vol. 46, 1990, pages 2587-2592.	
	C161	Zedeck, et al., *Mol. Phys.*, 1967, 3(4):386-95.	
	C162	Zinchenko, et al., "2', 3' & .5' – uridine methyl derivatives in microbiological transelicozilation." Doklady Akad Nauk v.297(3), pp. 731-734.	
	C163	Zinichenko, et al., "Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of Escherichia Coli." Nucleic Acids Research, Symposium Series No. 18., 1987, pp. 137-140.	
	C164	Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosporlases in whole cells of e. coli" Bioplymers & a cell, 1988, v. 4, No. 6.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	